Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37724848)

  • 1. Atypical (non-V600E) BRAF mutations in metastatic colorectal cancer in population and real-world cohorts.
    Osterlund E; Ristimäki A; Mäkinen MJ; Kytölä S; Kononen J; Pfeiffer P; Soveri LM; Keinänen M; Sorbye H; Nunes L; Salminen T; Nieminen L; Uutela A; Halonen P; Ålgars A; Sundström J; Kallio R; Ristamäki R; Lamminmäki A; Stedt H; Heervä E; Kuopio T; Sjöblom T; Isoniemi H; Glimelius B; Osterlund P
    Int J Cancer; 2024 Feb; 154(3):488-503. PubMed ID: 37724848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study.
    Uutela A; Osterlund E; Halonen P; Kallio R; Ålgars A; Salminen T; Lamminmäki A; Soveri LM; Ristamäki R; Lehtomäki K; Stedt H; Heervä E; Muhonen T; Kononen J; Nordin A; Ovissi A; Kytölä S; Keinänen M; Sundström J; Nieminen L; Mäkinen MJ; Kuopio T; Ristimäki A; Isoniemi H; Osterlund P
    Br J Cancer; 2022 Sep; 127(4):686-694. PubMed ID: 35610367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of Lynch syndrome, BRAF
    Zwart K; van der Baan FH; Cohen R; Aparicio T; de la Fouchardiére C; Lecomte T; Punt CJA; Sefrioui D; Verheijden RJ; Vink GR; Wensink GE; Zaanan A; Koopman M; Tougeron D; Roodhart JML
    Cancer Med; 2023 Aug; 12(15):15841-15853. PubMed ID: 37326121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of first-line cetuximab in wild-type RAS metastatic colorectal cancer according to tumour BRAF mutation status from the EREBUS cohort.
    Rouyer M; François E; Sa Cunha A; Monnereau A; Bignon E; Jové J; Lassalle R; Droz-Perroteau C; Moore N; Noize P; Fourrier-Réglat A; Smith D
    Br J Clin Pharmacol; 2021 Mar; 87(3):1120-1128. PubMed ID: 32656857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Metastasectomy in the Multimodality Approach for
    Johnson B; Jin Z; Truty MJ; Smoot RL; Nagorney DM; Kendrick ML; Kipp BR; Grothey A
    Oncologist; 2018 Jan; 23(1):128-134. PubMed ID: 28904173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
    Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
    Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States.
    Trunk A; Braithwaite M; Nevala-Plagemann C; Pappas L; Haaland B; Garrido-Laguna I
    J Natl Compr Canc Netw; 2022 Feb; 20(2):144-150. PubMed ID: 35130499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer.
    Prasanna T; Wong R; Price T; Shapiro J; Tie J; Wong HL; Nott L; Roder D; Lee M; Kosmider S; Jalali A; Burge M; Padbury R; Maddern G; Carruthers S; Moore J; Sorich M; Karapetis CS; Gibbs P; Yip D
    Curr Probl Cancer; 2021 Feb; 45(1):100637. PubMed ID: 32826083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
    Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
    Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.
    Shinozaki E; Yoshino T; Yamazaki K; Muro K; Yamaguchi K; Nishina T; Yuki S; Shitara K; Bando H; Mimaki S; Nakai C; Matsushima K; Suzuki Y; Akagi K; Yamanaka T; Nomura S; Fujii S; Esumi H; Sugiyama M; Nishida N; Mizokami M; Koh Y; Abe Y; Ohtsu A; Tsuchihara K
    Br J Cancer; 2017 Nov; 117(10):1450-1458. PubMed ID: 28972961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients.
    Rebersek M; Mesti T; Boc M; Ocvirk J
    Radiol Oncol; 2019 Mar; 53(1):85-95. PubMed ID: 30840593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS.
    Cannon TL; Randall JN; Sokol ES; Alexander SM; Wadlow RC; Winer AA; Barnett DM; Rayes DL; Nimeiri HS; McGregor KA
    Cancer Treat Res Commun; 2022; 32():100569. PubMed ID: 35567913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y
    BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of
    Stintzing S; Heinrich K; Tougeron D; Modest DP; Schwaner I; Eucker J; Pihusch R; Stauch M; Kaiser F; Kahl C; Karthaus M; Müller C; Burkart C; Reinacher-Schick A; Kasper-Virchow S; Fischer von Weikersthal L; Krammer-Steiner B; Prager GW; Taieb J; Heinemann V
    J Clin Oncol; 2023 Sep; 41(25):4143-4153. PubMed ID: 37352476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study.
    Guren TK; Thomsen M; Kure EH; Sorbye H; Glimelius B; Pfeiffer P; Österlund P; Sigurdsson F; Lothe IMB; Dalsgaard AM; Skovlund E; Christoffersen T; Tveit KM
    Br J Cancer; 2017 May; 116(10):1271-1278. PubMed ID: 28399112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer.
    Ilie MI; Long-Mira E; Hofman V; Mouroux J; Vignaud JM; Gauchotte G; Begueret H; Merlio JP; Emile JF; Hébuterne X; Hofman P
    Pathology; 2014 Jun; 46(4):311-5. PubMed ID: 24798160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments.
    Ros J; Matito J; Villacampa G; Comas R; Garcia A; Martini G; Baraibar I; Saoudi N; Salvà F; Martin Á; Antista M; Toledo R; Martinelli E; Pietrantonio F; Boccaccino A; Cremolini C; Dientsmann R; Tabernero J; Vivancos A; Elez E
    Ann Oncol; 2023 Jun; 34(6):543-552. PubMed ID: 36921693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?
    Wong V; Lee M; Wong R; Tie J; Shapiro J; Desai J; Nott L; Steel S; Burge M; Ma B; Khattak A; Hong W; Gibbs P
    Target Oncol; 2021 Mar; 16(2):227-236. PubMed ID: 33599905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.